Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners

AstraZeneca has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely-watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.

AstraZeneca dishes on its $500M new home in Cambridge, U.K.

AstraZeneca's sweeping new Cambridge, U.K., campus will be constructed with collaboration in mind, the company said, unveiling plans for the $500 million site it aims to open in 2016.

AstraZeneca spreads its virtual reach to cardio R&D with new partnership

AstraZeneca is expanding iMed, its virtual R&D project, through a cardiovascular-focused agreement with Germany's Max Planck Institute of Molecular Physiology that will focus on early-stage research.

AstraZeneca, MRC Technology renew preclinical pact

The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.

U.K. fund manager Neil Woodford bets big on AstraZeneca

Plenty of AstraZeneca fans voiced their support for a standalone company when Pfizer tried to take the drugmaker over earlier this year. But actions speak louder than words, and now one vocal advocate is putting his money where his mouth is.

Apparently confident AstraZeneca CEO socks $3.4M into company shares

Pascal Soriot has raised the stakes on AstraZeneca's turnaround. The chief executive plunked down $3.4 million to buy more of his company's shares. 

Another Pfizer bid for AstraZeneca? Investors weigh in

A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.

With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire--the latest totaling about $46.5 billion--it's not about to make Pfizer's same mistakes.

CDC committee recommends AZ's FluMist over flu shot in children

AstraZeneca's flu vaccine sales may have just gotten a boost, courtesy of federal regulators. Wednesday, they recommended that healthy children 2 to 8 years old receive the company's nasal spray flu vaccine FluMist in lieu of flu shots when available.

UPDATED: FDA experts spurn AstraZeneca's pitch for ovarian cancer drug olaparib

AstraZeneca's top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA's panel of outside experts on Wednesday, and they lost.